PE20160027A1 - Composiciones y metodos de construcciones quimericas del virus del dengue en vacunas - Google Patents

Composiciones y metodos de construcciones quimericas del virus del dengue en vacunas

Info

Publication number
PE20160027A1
PE20160027A1 PE2015001953A PE2015001953A PE20160027A1 PE 20160027 A1 PE20160027 A1 PE 20160027A1 PE 2015001953 A PE2015001953 A PE 2015001953A PE 2015001953 A PE2015001953 A PE 2015001953A PE 20160027 A1 PE20160027 A1 PE 20160027A1
Authority
PE
Peru
Prior art keywords
dengue virus
compositions
dengue
constructs
virus
Prior art date
Application number
PE2015001953A
Other languages
English (en)
Inventor
Claire Kinney
Richard M Kinney
Jill A Livengood
Dan T Stinchcomb
Original Assignee
Takeda Vaccines Inc
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Vaccines Inc, Us Gov Health & Human Serv filed Critical Takeda Vaccines Inc
Publication of PE20160027A1 publication Critical patent/PE20160027A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • C07K14/1816—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus), border disease virus
    • C07K14/1825—Flaviviruses or Group B arboviruses, e.g. yellow fever virus, japanese encephalitis, tick-borne encephalitis, dengue
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C12N15/8613—Chimaeric vector systems comprising heterologous sequences for production of another viral vector
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24141—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • C12N2770/24162—Methods of inactivation or attenuation by genetic engineering
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

La presente invencion se refiere a composiciones, usos y manufactura de construcciones del virus del dengue y virus del vengue vivos atenuados. En ciertas modalidades, la composicion puede incluir, pero no se limita a una composicion tetravalente del virus del dengue. En ciertas modalidades, las composiciones pueden incluir construcciones de uno o mas serotipos del virus del dengue, tales como las construcciones del virus dengue-1 (DEN-1), el virus dengue-2 (DEN-2), los virus dengue-3 (DEN 3) o dengue-4 (DEN-4). En otras modalidades, las construcciones descritas en esta invencion pueden combinarse en una composicion para generar una vacuna contra una o mas construcciones de virus del dengue que pueden o no ser subsecuentemente pasadas a celulas de mamiferos
PE2015001953A 2013-03-15 2014-03-12 Composiciones y metodos de construcciones quimericas del virus del dengue en vacunas PE20160027A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361800204P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
PE20160027A1 true PE20160027A1 (es) 2016-01-28

Family

ID=50678274

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2015001953A PE20160027A1 (es) 2013-03-15 2014-03-12 Composiciones y metodos de construcciones quimericas del virus del dengue en vacunas
PE2021000217A PE20211814A1 (es) 2013-03-15 2014-03-12 Composiciones y metodos de construcciones quimericas del virus del dengue en vacunas

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2021000217A PE20211814A1 (es) 2013-03-15 2014-03-12 Composiciones y metodos de construcciones quimericas del virus del dengue en vacunas

Country Status (32)

Country Link
US (5) US9783579B2 (es)
EP (5) EP2968516B1 (es)
JP (2) JP6818548B2 (es)
KR (3) KR102389908B1 (es)
CN (5) CN113637693A (es)
AR (2) AR095598A1 (es)
AU (2) AU2014235476B2 (es)
CA (4) CA3166063A1 (es)
CR (1) CR20150569A (es)
DK (1) DK4129330T3 (es)
DO (1) DOP2015000232A (es)
EC (1) ECSP23013715A (es)
ES (2) ES2965652T3 (es)
FI (2) FI3539565T3 (es)
FR (1) FR22C1064I1 (es)
HK (1) HK1220359A1 (es)
HR (1) HRP20231581T1 (es)
HU (2) HUE061507T2 (es)
LT (1) LT4129330T (es)
MX (5) MX2015012893A (es)
MY (1) MY187796A (es)
NL (1) NL301223I2 (es)
NZ (1) NZ630869A (es)
PE (2) PE20160027A1 (es)
PH (1) PH12015502120A1 (es)
PL (1) PL3539565T3 (es)
PT (1) PT3539565T (es)
SG (3) SG10201913387XA (es)
SI (1) SI4129330T1 (es)
TW (3) TWI726312B (es)
UY (1) UY35489A (es)
WO (1) WO2014150939A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ630869A (en) * 2013-03-15 2017-11-24 Us Gov Health & Human Services Compositions and methods for dengue virus chimeric constructs in vaccines
US10004795B2 (en) * 2015-09-08 2018-06-26 Fundacao Butantan Process for preparing an attenuated tetravalent dengue vaccine
MY194650A (en) * 2015-11-27 2022-12-09 Km Biologics Co Ltd Multivalent dengue vaccine composition comprising a mixture of attenuated dengue viruses from different serotypes
CN109069615A (zh) * 2016-04-13 2018-12-21 武田疫苗股份有限公司 在儿童和年轻人中针对登革热病毒接种疫苗的组合物和方法
US11464815B2 (en) 2018-09-05 2022-10-11 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof
EP3846849A1 (en) 2018-09-05 2021-07-14 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof
US11426461B2 (en) 2018-09-05 2022-08-30 Takeda Vaccines, Inc. Methods for preventing dengue and hepatitis A
US20240076631A2 (en) 2020-02-27 2024-03-07 Takeda Vaccines, Inc. Method for removing host cell dna from virus preparation
WO2021173597A1 (en) * 2020-02-28 2021-09-02 Merck Sharp & Dohme Corp. Dengue serotype specific rt-pcr multiplex assay
WO2023147342A2 (en) 2022-01-25 2023-08-03 Takeda Vaccines, Inc. Large-scale flaviviral vaccine production and manufacture
WO2023158989A1 (en) 2022-02-15 2023-08-24 Takeda Vaccines, Inc. Dengue vaccine batch mixing process
WO2023215383A1 (en) 2022-05-04 2023-11-09 Takeda Vaccines, Inc. Computer-based determination of flavivirus infectivity

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5276941A (en) 1975-12-23 1977-06-28 Ito Masato Method of conversing infrared rays
US4810092A (en) 1986-02-21 1989-03-07 Midac Corporation Economical spectrometer unit having simplified structure
JPH0768267B2 (ja) 1986-06-05 1995-07-26 財団法人阪大微生物病研究会 フラビウイルス抗原
JPH084508B2 (ja) 1987-09-16 1996-01-24 国立予防衛生研究所長 組み換えワクチニアウイルス
JP2511494B2 (ja) 1988-05-12 1996-06-26 善治 松浦 日本脳炎ウイルス表面抗原蛋白質の製造法
US6184024B1 (en) 1988-07-14 2001-02-06 The United States Of America As Represented By The Department Of Health And Human Services Chimeric and/or growth-restricted flaviviruses
IL91304A0 (en) 1988-08-20 1990-03-19 Us Health Recombinant vaccinia virus for prevention of disease caused by flavivirus
US5514375A (en) 1990-08-15 1996-05-07 Virogenetics Corporation Flavivirus recombinant poxvirus vaccine
MY109299A (en) 1990-08-15 1996-12-31 Virogenetics Corp Recombinant pox virus encoding flaviviral structural proteins
US5494671A (en) 1990-08-27 1996-02-27 The United States Of America As Represented By The Department Of Health And Human Services C-terminally truncated dengue and Japanese encephalitis virus envelope proteins
DK0604566T3 (da) 1991-09-19 2000-04-10 Us Health Kimærisk og/eller vækstbegrænsede flavivirus
JPH05276941A (ja) 1992-02-28 1993-10-26 Nippon Zeon Co Ltd フラビウイルス科に属するウイルスの表面抗原タンパク質を含む非感染性の構造物粒子の製造方法
PT836482E (pt) 1995-05-24 2003-02-28 Hawaii Biotech Group Vacina subunitaria contra infeccao por flavirus
WO1996040933A1 (en) * 1995-06-07 1996-12-19 The Government Of The United States Of America, Represented By The Secretary Department Of Health And Human Services Infectious dengue 2 virus pdk-53 as quadravalent vaccine
IL131600A0 (en) 1997-02-28 2001-01-28 Ora Vax Inc Chimeric flavivirus vaccines
DE69833002T2 (de) 1997-10-08 2006-08-24 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Chimärer impfstoff gegen das zeckenenzephalitis virus
WO1999063095A1 (en) 1998-06-04 1999-12-09 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Nucleic acid vaccines for prevention of flavivirus infection
WO2001039802A1 (en) * 1999-12-01 2001-06-07 Oravax, Inc. Chimeric flavivirus vaccines
ES2374131T3 (es) 2000-02-16 2012-02-14 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Flavivirus quiméricos avirulentos e inmunógenos.
EP1159968B1 (fr) * 2000-05-30 2008-10-29 Mahidol University Souches atténuées du virus de la Dengue et leur utilisation dans une composition vaccinale
CA2440593A1 (en) 2001-03-12 2002-09-19 Yale University Compositions and methods comprising west nile virus polypeptides
CA2611934C (en) * 2005-06-17 2015-11-03 Sanofi Pasteur Dengue serotype 1 attenuated strain
DE602006015807D1 (de) * 2005-06-17 2010-09-09 Ct S For Disease Control & Pre Abgeschwächter dengue-serotyp-2-stamm
KR20070017759A (ko) 2005-08-08 2007-02-13 삼성전자주식회사 초해상 정보 저장 매체, 기록/재생 장치 및 기록/재생 방법
JP5227172B2 (ja) * 2005-08-10 2013-07-03 サノフィ パスツール バイオロジクス リミテッド ライアビリティ カンパニー デングウイルス感染に対するワクチン接種
US7968102B2 (en) * 2006-01-13 2011-06-28 Sanofi Pasteur S.A. Dengue chimeric viruses
HUE029333T2 (en) * 2006-08-15 2017-03-28 The Government Of The U S A As Repr By The Secretary Dept Of Health & Human Services The Nat Inst Of Development of Dengue virus vaccine components
DK2178903T3 (da) 2007-07-13 2012-06-18 Florida Gulf Coast University Optimeret denguevirus-adgangsinhiberede peptid (DN81)
WO2009134717A1 (en) * 2008-04-30 2009-11-05 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Chimeric west nile/dengue viruses
SG157244A1 (en) 2008-05-15 2009-12-29 Mp Biomedicals Asia Pacific Pte Ltd Point of care test for the detection of exposure or immunity to dengue virus
JP5276941B2 (ja) 2008-09-24 2013-08-28 株式会社村田製作所 大変位アクチュエータ
WO2010085358A2 (en) * 2009-01-23 2010-07-29 The Board Of Regents Of The University Of Texas System Flaviviruses expressing the prm, e, and ns1 proteins of other flaviviruses and uses thereof
WO2013188315A1 (en) 2012-06-10 2013-12-19 Inviragen, Inc. Compositions and methods for administration of vaccines against dengue virus
US8968996B2 (en) 2009-06-01 2015-03-03 Takeda Vaccines, Inc. Compositions and methods for rapid immunization against dengue virus
JP5848243B2 (ja) 2009-06-01 2016-01-27 タケダ ワクチン, インコーポレイテッドTakeda Vaccines, Inc. デングウイルスに対する免疫原性組成物
CN101560520A (zh) * 2009-06-04 2009-10-21 中国疾病预防控制中心病毒病预防控制所 乙脑/登革嵌合病毒及其应用
BRPI0904020B8 (pt) * 2009-10-01 2021-05-25 Fundacao Oswaldo Cruz composição vacinal contra o vírus da dengue, e, kit
EP2353609A1 (en) 2010-02-04 2011-08-10 Sanofi Pasteur Immunization compositions and methods
PE20150356A1 (es) 2012-07-24 2015-03-20 Sanofi Pasteur Composiciones de vacuna para la prevencion contra la infeccion por el virus del dengue
MY197723A (en) 2012-07-24 2023-07-10 Sanofi Pasteur Vaccine compositions for the prevention of dengue virus infection
TW201920677A (zh) * 2012-11-08 2019-06-01 美商武田疫苗股份有限公司 登革熱病毒血清型４型之建構物的組成物、方法及用途
JP2016504315A (ja) * 2012-12-14 2016-02-12 タケダ ワクチン, インコーポレイテッドTakeda Vaccines, Inc. 三価デングウイルス製剤に関する組成物、投与方法および使用
NZ630869A (en) 2013-03-15 2017-11-24 Us Gov Health & Human Services Compositions and methods for dengue virus chimeric constructs in vaccines
TW201620546A (zh) 2014-09-02 2016-06-16 賽諾菲巴斯德公司 疫苗組合物
WO2017005654A1 (en) 2015-07-03 2017-01-12 Sanofi Pasteur Concomitant dengue, diphtheria, tetanus, whooping cough (pertussis), polio, and haemophilus influenzae type b vaccination.
EP3316905A1 (en) 2015-07-03 2018-05-09 Sanofi Pasteur Concomitant dengue and yellow fever vaccination
US10004795B2 (en) 2015-09-08 2018-06-26 Fundacao Butantan Process for preparing an attenuated tetravalent dengue vaccine
CN109069615A (zh) 2016-04-13 2018-12-21 武田疫苗股份有限公司 在儿童和年轻人中针对登革热病毒接种疫苗的组合物和方法
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
WO2019077622A1 (en) 2017-10-16 2019-04-25 Serum Institute Of India Private Limited STABLE VACCINE COMPOSITIONS COMPRISING, BOTH, A LIVING RECOMBINANT FLAVIVUS ATTENUATED AND PROCESS FOR PREPARING THE SAME
US11464815B2 (en) 2018-09-05 2022-10-11 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof

Also Published As

Publication number Publication date
PE20211814A1 (es) 2021-09-14
SG10201913387XA (en) 2020-02-27
US20170290884A1 (en) 2017-10-12
AR123702A2 (es) 2023-01-04
TW201516147A (zh) 2015-05-01
BR112015023635A8 (pt) 2021-12-14
EP3539565A1 (en) 2019-09-18
MX2015012893A (es) 2016-04-04
EP2968516A2 (en) 2016-01-20
CN113637086A (zh) 2021-11-12
MX2019003602A (es) 2022-06-27
NZ735336A (en) 2021-04-30
MX2023000349A (es) 2023-04-24
AU2019216724B2 (en) 2021-03-04
US20230181682A1 (en) 2023-06-15
US20220062375A1 (en) 2022-03-03
EP4183411A1 (en) 2023-05-24
CA2903231A1 (en) 2014-09-25
CN113637693A (zh) 2021-11-12
PT3539565T (pt) 2023-04-12
SG11201507460PA (en) 2015-10-29
EP3689374A1 (en) 2020-08-05
HUE061507T2 (hu) 2023-07-28
JP2016513970A (ja) 2016-05-19
BR122021015503A2 (pt) 2021-12-14
US10449231B2 (en) 2019-10-22
BR122021015502A2 (pt) 2021-12-14
HRP20231581T1 (hr) 2024-03-15
FI3539565T3 (fi) 2023-04-19
US9783579B2 (en) 2017-10-10
SG10201913435TA (en) 2020-03-30
TW201945545A (zh) 2019-12-01
EP4129330B1 (en) 2023-09-06
CA3177572A1 (en) 2014-09-25
DK4129330T3 (da) 2023-12-11
KR20160002780A (ko) 2016-01-08
PL3539565T3 (pl) 2023-09-25
MY187796A (en) 2021-10-24
CA3166063A1 (en) 2014-09-25
SI4129330T1 (sl) 2024-02-29
WO2014150939A2 (en) 2014-09-25
AU2014235476A1 (en) 2015-09-24
KR102626270B1 (ko) 2024-01-19
CA3177574A1 (en) 2014-09-25
HUS2300022I1 (hu) 2023-08-28
US11931399B2 (en) 2024-03-19
EP4129330A1 (en) 2023-02-08
KR20240014580A (ko) 2024-02-01
EP2968516B1 (en) 2022-01-12
CN113637694A (zh) 2021-11-12
ES2965652T3 (es) 2024-04-16
FR22C1064I1 (fr) 2023-02-03
HK1220359A1 (zh) 2017-05-05
WO2014150939A3 (en) 2014-12-31
EP3689374B1 (en) 2022-11-02
CR20150569A (es) 2016-04-01
AU2019216724C1 (en) 2021-08-26
ES2933970T3 (es) 2023-02-15
AU2014235476B2 (en) 2019-05-16
US20200061151A1 (en) 2020-02-27
US20140302088A1 (en) 2014-10-09
TW202144573A (zh) 2021-12-01
MX2023000354A (es) 2023-02-13
DOP2015000232A (es) 2016-02-29
LT4129330T (lt) 2023-12-27
BR112015023635A2 (pt) 2018-06-05
NL301223I2 (nl) 2023-07-26
MX2023000353A (es) 2023-02-13
KR20220054892A (ko) 2022-05-03
JP6818548B2 (ja) 2021-01-20
TWI733646B (zh) 2021-07-21
TWI726312B (zh) 2021-05-01
AR095598A1 (es) 2015-10-28
FIC20230021I1 (fi) 2023-06-27
PH12015502120A1 (en) 2016-01-25
EP3539565B1 (en) 2023-01-11
CN105451763B (zh) 2021-06-18
UY35489A (es) 2014-10-31
NZ630869A (en) 2017-11-24
KR102389908B1 (ko) 2022-04-26
JP7050031B2 (ja) 2022-04-07
ECSP23013715A (es) 2023-04-28
AU2019216724A1 (en) 2019-09-05
CN111778263A (zh) 2020-10-16
CN105451763A (zh) 2016-03-30
JP2019146594A (ja) 2019-09-05

Similar Documents

Publication Publication Date Title
ECSP23013715A (es) Composiciones y métodos de construcciones quiméricas del virus del dengue en vacunas
AR093421A1 (es) Composiciones, metodos y usos de construcciones de virus del dengue de serotipo-4
CO2018011355A2 (es) Composiciones y métodos de vacunación contra virus de dengue en niños y adultos jóvenes
MX336687B (es) Tratamiento y prevencion de infecciones del virus del dengue.
PE20140646A1 (es) Vacuna de virus de dengue inactivado
UY35013A (es) Composiciones farmacéuticas que contienen un antagonista de il-4r y sus usos
AR095021A1 (es) Composiciones de azúcares mixtos
CU20110219A7 (es) Composiciones y métodos para administración de vacunas contra virus del dengue
PE20110992A1 (es) Composicion inmunogenica que comprende un antigeno del virus del dengue
PE20151769A1 (es) Variantes de pertuzumab y su evalaucion
BR112015001313A2 (pt) composições de vacina
AR096863A1 (es) Composiciones de caucho natural mejoradas
CO6440541A2 (es) Virus de diarrea viral bovina con una proteina erns modificada
BR112018077540A2 (pt) vírus quimérico da dengue/zika como vacinas de zika vírus vivo atenuado
WO2015095735A3 (en) Vaccine compositions and uses thereof
CL2011001034A1 (es) Compuestos derivados de pirrolidina; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como endometriosis, fibroides uterinos, menorragia, entre otras.
CR20180457A (es) Construcciones de alfavirus vivos atenuados y métodos y usos del mismo
BR112016029201A2 (pt) vírus do oeste do nilo/dengue quiméricos e métodos de uso
TH170668A (th) องค์ประกอบ และวิธีการสำหรับชุดโครงสร้างไคมีริกไวรัสเด็งกีในวัคซีน
CO2021017772A2 (es) Virus del dengue atenuados
MX350236B (es) Composiciones de peptidos para el tratamiento y diagnostico de la fiebre por virus del dengue.
CO6321231A2 (es) Imidazolil-bifenil-imidazoles como inhibidores del virus de la hepatitis c